Hansoh Pharmaceutical's (HKG:3692) HS-20093 for injection in combination with adebrelimab obtained approval to be included as a Breakthrough Therapy Designated Drug from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The approval is for the indication of locally advanced or metastatic non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.